Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Faricimab shows therapeutic potential for diabetic macular oedema

19 Aug 2019

Dual inhibition of angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A with faricimab induces meaningful and superior visual acuity improvements compared with ranibizumab in patients with diabetic macular oedema (DME), according to the results of the phase II BOULEVARD trial.

BOULEVARD included 229 adult patients, among whom 168 were treatment-naïve and 61 were previously treated with anti-VEGF. All patients had centre-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) 325 μm.

Treatment-naïve patients were randomly assigned to treatment with intravitreal faricimab at 6.0 mg or 1.5 mg or ranibizumab 0.3 mg. Those with previous exposure to anti-VEGF were randomized to faricimab 6.0 mg or ranibizumab 0.3 mg. Treatment was given monthly for 20 weeks, followed by an observation period up to week 36 to assess durability.

The present trial met its primary endpoint of change in BCVA from baseline at week 24 in treatment-naïve patients. Mean improvements were 13.9 ETDRS letters in the 6.0-mg faricimab group, 11.7 letters in the 1.5-mg faricimab group and 10.3 letters in the ranibizumab group. The visual acuity gain obtained with the 6.0-mg dose was significantly higher than that obtained with ranibizumab (mean difference, 3.6 letters; p=0.03).

In both patient populations, faricimab was associated with dose-dependent reductions in CST, improvements in Diabetic Retinopathy Severity Scale score and longer time to retreatment during the observation period as compared with ranibizumab.

The study drug was well tolerated and showed no new or unexpected safety signals.

Additional long-term benefits of drying the retina, along with the anti-inflammatory properties of faricimab, will be investigated in further studies, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]